Steven Blotner

2.1k total citations · 1 hit paper
36 papers, 1.1k citations indexed

About

Steven Blotner is a scholar working on Oncology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Steven Blotner has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Infectious Diseases and 10 papers in Molecular Biology. Recurrent topics in Steven Blotner's work include HIV/AIDS drug development and treatment (13 papers), Cancer-related Molecular Pathways (9 papers) and Retinal Diseases and Treatments (6 papers). Steven Blotner is often cited by papers focused on HIV/AIDS drug development and treatment (13 papers), Cancer-related Molecular Pathways (9 papers) and Retinal Diseases and Treatments (6 papers). Steven Blotner collaborates with scholars based in United States, Canada and United Kingdom. Steven Blotner's co-authors include Razelle Kurzrock, Katja Schulze, Vaikunth Cuchelkar, Funda Meric‐Bernstam, Charles Swanton, John D. Hainsworth, Christopher J. Sweeney, Ron Bose, David R. Spigel and Howard A. Burris and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Steven Blotner

34 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

2019 383 citations Funda Meric‐Bernstam, Herbert I. Hurwitz et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Blotner United States	17	598	257	223	178	177	36	1.1k
He Huang China	19	480 0.8×	537 2.1×	159 0.7×	217 1.2×	297 1.7×	78	1.4k
Giorgio Bovo Italy	23	498 0.8×	429 1.7×	488 2.2×	155 0.9×	205 1.2×	63	1.5k
Michael Doukas Netherlands	18	414 0.7×	174 0.7×	301 1.3×	174 1.0×	83 0.5×	66	1.1k
Eva Honsová Czechia	19	177 0.3×	230 0.9×	283 1.3×	141 0.8×	79 0.4×	73	1.3k
Antonia Digklia Switzerland	13	443 0.7×	293 1.1×	331 1.5×	211 1.2×	212 1.2×	61	1.1k
Sameh Mikhail United States	22	747 1.2×	270 1.1×	415 1.9×	229 1.3×	322 1.8×	70	1.5k
Tongyu Lin China	17	484 0.8×	216 0.8×	139 0.6×	230 1.3×	108 0.6×	71	1.1k
Pei-Rong Ding China	20	1.2k 2.0×	195 0.8×	271 1.2×	69 0.4×	271 1.5×	45	1.6k
Francesco De Rosa Italy	18	694 1.2×	291 1.1×	168 0.8×	89 0.5×	102 0.6×	58	1.1k
Darrin Despain United States	14	322 0.5×	172 0.7×	704 3.2×	101 0.6×	113 0.6×	28	1.5k

Countries citing papers authored by Steven Blotner

Since Specialization

Citations

This map shows the geographic impact of Steven Blotner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Blotner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Blotner more than expected).

Fields of papers citing papers by Steven Blotner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Blotner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Blotner. The network helps show where Steven Blotner may publish in the future.

Co-authorship network of co-authors of Steven Blotner

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Blotner. A scholar is included among the top collaborators of Steven Blotner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Blotner. Steven Blotner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sheth, Veeral, Nancy M. Holekamp, Arshad M. Khanani, et al.. (2024). Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections. Ophthalmology Retina. 9(4). 330–342.

Bhisitkul, Robert B., Peter A. Campochiaro, Steven Blotner, et al.. (2024). Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumab. British Journal of Ophthalmology. 108(9). 1216–1225. 1 indexed citations

Baumal, Caroline R., Steven Blotner, Anne E. Fung, & Carlos Quezada-Ruiz. (2022). Drusen Characteristics and Age-Related Macular Degeneration in Fellow Eyes. Ophthalmology Retina. 6(10). 969–971. 2 indexed citations

Freund, K. Bailey, Giovanni Staurenghi, Jesse J. Jung, et al.. (2022). Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR. Graefe s Archive for Clinical and Experimental Ophthalmology. 260(8). 2437–2447. 12 indexed citations

Sheth, Veeral, et al.. (2022). Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmology. 7(1). e000957–e000957. 9 indexed citations

Recchia, Franco M., Steven Blotner, Natasha Singh, Giulio Barteselli, & Shamika Gune. (2020). Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD: End of Study Results. Investigative Ophthalmology & Visual Science. 61(7). 1155–1155. 1 indexed citations

Bhisitkul, Robert B., et al.. (2020). Clinical trial versus real-world outcomes with anti-VEGF therapy for branch and central retinal vein occlusion. Investigative Ophthalmology & Visual Science. 61(7). 1304–1304.

Kurzrock, Razelle, Daniel W. Bowles, Hyunseok Kang, et al.. (2020). Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Annals of Oncology. 31(3). 412–421. 79 indexed citations

Uy, Geoffrey L., Sarit Assouline, Steven Blotner, et al.. (2020). Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. Investigational New Drugs. 38(5). 1430–1441. 16 indexed citations

10.

Pápai, Zsuzsanna, Lin-Chi Chen, Daniel Da Costa, et al.. (2019). A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors. Cancer Chemotherapy and Pharmacology. 84(1). 93–103. 14 indexed citations

11.

Meric‐Bernstam, Funda, Herbert I. Hurwitz, Kanwal Raghav, et al.. (2019). Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. The Lancet Oncology. 20(4). 518–530. 383 indexed citations breakdown →

12.

Razak, Albiruni R. Abdul, Wilson H. Miller, Geoffrey L. Uy, et al.. (2019). A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. Investigational New Drugs. 38(4). 1156–1165. 13 indexed citations

13.

Blotner, Steven, Lin-Chi Chen, Cristiano Ferlini, & Jianguo Zhi. (2018). Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML. Cancer Chemotherapy and Pharmacology. 81(3). 597–607. 12 indexed citations

14.

Nemunaitis, John, Annie Young, Samuel Ejadi, et al.. (2018). Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 81(3). 529–537. 16 indexed citations

15.

Morcos, Peter N., et al.. (2013). Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate. European Journal of Clinical Pharmacology. 69(10). 1777–1784. 34 indexed citations

16.

Reddy, Micaela B., Yuan Chen, Joshua Haznedar, et al.. (2012). Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics. Clinical Pharmacokinetics. 51(7). 457–465. 16 indexed citations

17.

Haznedar, Joshua, Jennifer Fretland, Geraldine Leong, et al.. (2010). 753 IMPACT OF LOW DOSE RITONAVIR BOOSTING ON THE PHARMACOKINETICS OF RG7227 (ITMN-191), A HIGHLY POTENT AND SELECTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE. Journal of Hepatology. 52. S293–S293. 6 indexed citations

18.

Ahnen, Dennis J., et al.. (2007). Effect of Orlistat on Fecal Fat, Fecal Biliary Acids, and Colonic Cell Proliferation in Obese Subjects. Clinical Gastroenterology and Hepatology. 5(11). 1291–1299. 13 indexed citations

19.

Prati, Daniele, Mitchell L. Shiffman, M. Diago, et al.. (2006). Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. Journal of Hepatology. 44(4). 679–685. 34 indexed citations

20.

Weinblatt, Michael E., Richard P. Polisson, Steven Blotner, et al.. (1993). The effects of drug therapy on radiographic progression of rheumatoid arthritis. results of a 36‐week randomized trial comparing methotrexate and auranofin. Arthritis & Rheumatism. 36(5). 613–619. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact